



Training the Next Generation of Researchers in the Organ-on-Chip Field

Alessia Moruzzi^{1,2}, Tanvi Shroff^{1,2}, Silke Keller^{1,2,3}, Peter Loskill^{1,2,3,*} and Madalena Cipriano^{1,3,*}

- ¹ Department for Microphysiological Systems, Institute of Biomedical Engineering, Eberhard Karls University Tübingen, 72074 Tuebingen, Germany
- ² NMI Natural and Medical Sciences Institute at the University of Tübingen, 72770 Reutlingen, Germany
- ³ 3R-Center for In Vitro Models and Alternatives to Animal Testing, Eberhard Karls University Tübingen, 72074 Tuebingen, Germany
- * Correspondence: peter.loskill@uni-tuebingen.de (P.L.); madalena.cipriano@medizin.uni-tuebingen.de (M.C.)

Abstract: Organ-on-chip (OoC) technology bridges the principles of biology and engineering to create a new generation of in vitro models and involves highly interdisciplinary collaboration across STEM disciplines. Training the next generation of scientists, technicians and policy makers is a challenge that requires a tailored effort. To promote the qualification, usability, uptake and long-term development of OoC technology, we designed a questionnaire to evaluate the key aspects for training, identify the major stakeholders to be trained, their professional level and specific skillset. The 151 respondents unanimously agreed on the need to train the next generation of OoC researchers and that the training should be provided early, in interdisciplinary subjects and throughout the researchers' career. We identified two key training priorities: (i) training scientists with a biology background in microfabrication and microfluidics principles and (ii) training OoC developers in pharmacology/toxicology. This makes training in OoC a transdisciplinary challenge rather than an interdisciplinary one. The data acquired and analyzed here serves to guide training initiatives for preparing competent and transdisciplinary researchers, capable of assuring the successful development and application of OoC technologies in academic research, pharmaceutical/chemical/cosmetic industries, personalized medicine and clinical trials on chip.

Keywords: organ-on-chip; interdisciplinary training; training needs

1. Introduction

The last decade has seen the emergence of Organ-on-Chip (OoC) systems, which are defined as "fit-for-purpose microfluidic devices, containing living engineered organ substructures in a controlled microenvironment, that recapitulate one or more aspects of the organ's dynamics, functionality and (patho)physiological response in vivo under real-time monitoring" [1]. The technology promises great potential for human-based translational [2] and personalized medicine [3]; for the reduction of pharmaceutical R&D costs [4,5]; and, through the generation of mechanistic knowledge, can be a game-changer towards the 3Rs and the transition to non-animal science [6,7]. The OoC field is characterized by a high degree of interdisciplinarity and draws upon technologies and concepts from various fields. Approaches from engineering, physics and chemistry enable precise spatiotemporal manipulation and monitoring of cells and liquids. Techniques from molecular and cell biology allow for the recapitulation and investigation of cell and tissue function as well as accurate cellular microenvironments [8]. Guidelines from clinical science, toxicology and pharmacology define the applications of these models [9]. The emergence and development of the OoC field stems from significant progress in related fields: Advances in microfabrication techniques enabled the generation of polymer structures on cellular scales. Breakthroughs in stem cell research paved the way for fully human tissue models. New approaches in molecular biology and imaging allowed for small-scale and high-throughput



Citation: Moruzzi, A.; Shroff, T.; Keller, S.; Loskill, P.; Cipriano, M. Training the Next Generation of Researchers in the Organ-on-Chip Field. *Educ. Sci.* **2023**, *13*, 144. https://doi.org/10.3390/ educsci13020144

Academic Editors: P. Carmona Marques and J. Robert Nogueira

Received: 29 November 2022 Revised: 17 January 2023 Accepted: 18 January 2023 Published: 30 January 2023



Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/). readouts. The development of novel sensor technologies enabled long-term monitoring of living systems. The OoC field, however, is still in its infancy, with a variety of challenges impeding the broad adoption of OoC models in academic, clinical and industrial research [10–12]. Challenges such as the recapitulation of complex tissues, cell maturity, large scale chip production, quality assurance, standardization, facilitation of usability, regulatory acceptance and many others are yet to be addressed [1,5,10,12–15].

To overcome these challenges, it is imperative to train experts in this multidisciplinary technology at different levels of education and work function. Importantly, one must consider that experts have different STEM identities [16], distinct primary STEM education fields that can range across physics and biology to engineering, different ways to approach problems and different perceptions depending on their experience level [17]. Thus, targeted and well-defined training strategies that foster interdisciplinary work and communication for professionals must be defined and implemented. Additionally, early training initiatives targeting undergraduate and graduate students should aim at integrating disciplines in an transdisciplinary rather than an interdisciplinary context [18]. Choi and Pak, 2006, defined multidisciplinarity by drawing knowledge from different disciplines; and transdisciplinarity by the integration of disciplines transcending their traditional boundaries [19].

The assessment of training needs has been performed previously in emerging fields such as data analysis [20], metabolomics [21] and applied health research [22]. Training efforts in novel technologies must consider a combination of theoretical and practical immersive pedagogy with exposure to workflows and processes and addition to curricula. Moreover, such training efforts should also encompass non-technical topics such as bioethics, data privacy, trial management and personal safety [23].

The aim of this study is the identification of the training priorities, key skill sets and adequate types of training required to prepare the next generation of researchers to advance the OoC field and possibly change the way how we perform biomedical, pharmaceutical and toxicological research. Researchers working in the OoC field take on many different roles: *scientists-as-developers, scientists as end-users* in *academia* and *industry, technicians, clinicians,* and *scientists as decision makers.* Each of these "stakeholders" requires a specific amount and type of training to successfully adopt OoC technology. To identify stakeholder-specific requirements, we conducted a survey aimed at providing an objective assessment of training needs. Experts actively working in the OoC field from different sectors, disciplines and career stages were asked to complete a questionnaire focused on three main overarching questions:

- Which aspects of training are most important for the overall development of the OoC field?
- Which specific type of training in the OoC field should each stakeholder receive?
- What is the amount of training that each stakeholder should receive to achieve a certain level of experience in the OoC field?

2. Materials and Methods

2.1. Survey Description and Recruiting Method

The evaluation of training needs was based on a structured questionnaire accessible via the EUSurvey website from 15 January 2019 to 12 June 2020. Stakeholders from the OoC field were invited to participate via direct email, newsletters and social media (e.g., Twitter, LinkedIn, ResearchGate). The questionnaire (Supplementary file S1) comprised of 15 questions and was completed by 151 respondents. A total of 122 respondents answered all questions. Supplementary file S2 includes a table with an overview of the number of respondents that answered each question, as well as all analyzed data used to generate the figures. The specific questions in the survey are listed below:

• Q1. How would you define yourself as a professional? (a) Type of institution; (b) Job level; (c) Field of work; (d) Field of Graduate University education (Bachelor's Degree);

(e) Field of first Postgraduate University education (Master's Degree); (f) Field of second Postgraduate University education (Doctorate Degree); (g) Main area of expertise

- Q2. Select the tissues/organs/systems/biological functions with which you are familiar and/or you work with?
- Q3. Select the microfabrication techniques for polymer-based microfluidic devices with which you are familiar and/or you work with?
- Q4. How important are the following aspects for the Organ-on-Chip field development?
- Q5. How important is it to provide specific training for each of the following stakeholders, to promote the Organ-on-Chip systems qualification, usability, uptake and/or long-term development?
- Q6. At which level do you consider that specific training is necessary to promote the Organ-on-Chip systems qualification, usability, uptake and/or long-term development?
- Q7–12. How important are the following elements to consider for training, for Scientistsas-developers /end users (Academia/Industry)/decision makers/technicians/ clinicians regarding the improvement of Organ-on-Chip systems qualification, usability, uptake and/or long-term development?
- Q13. What is the most adequate complexity level of specific training for each of the following stakeholders, to promote Organ-on-Chip systems qualification, usability, uptake and/or long-term development?
- Q14. What is the most adequate amount of specific training for each of the following stakeholders, to promote Organ-on-Chip systems qualification, usability, uptake and/or long-term development?
- Q15. How important would it be to include the topic of Organ-on-Chip technologies as a seminar of course in the following broader field(s) of education?

2.2. Methods of Data Analysis

The raw data was exported from the EUSurvey platform as a Microsoft Excel spreadsheet and was further analyzed in Excel 2019 using power query scripts to perform comparative analyses. The raw data is included in Supplementary file S3 with the integrated data analysis scripts.

Given the breadth of survey responses, certain factors were taken into consideration during data analysis. First, answers from respondents who did not specify their job level or selected multiple job levels were excluded from the analysis, thus reducing the number of respondents from 151 to 149. Second, whenever a respondent selected the option "Other (please specify) _____" and typed in the specific answer, we assessed the response on a case-by-case basis and determined whether to included it in one of the available options or to categorize it indeed as other. This is described in detail in the "Substitution Tables" (Supplementary file S3).

Q1, Q2, Q3, Q6, Q14 and Q15 were analyzed by counting the number of respondents for each option. Because multiple answers were allowed, the total number of answers outnumbers the total number of respondents. Additionally, we counted how many respondents from Q2 and Q3 were familiar with more than one Microfabrication technique or more than one organ.

For Q6, we also analyzed which combinations of educational levels (Undergraduate, Master, Doctorate and Postdoctoral) were selected by most respondents.

The questions asking to grade the degree of importance (Q4, Q5, Q7–12 and Q15) were analyzed by assigning values to the options to generate a ranking as follows: Very important = 4; Somewhat important = 3; Less important = 2; Not important = 1. This ranking system was chosen to reveal the highest contrast across responses within the different categories, thus enabling clear conclusions to be drawn from the graphs. We excluded respondents who skipped a question and those who answered "not sure". Q15 was available only to those respondents who considered it important to include training in a specific course for at least one stakeholder in Q14. The data was plotted as heatmap of

the ranking number and wherever relevant, the proportion of respondents was included in the text.

2.3. Subgrouping of the Respondents

The respondents were categorized in accordance with:

- Work experience: PhD candidates 46% (69 respondents) versus senior scientists 51% (79 respondents)—respondents pursuing a doctoral degree compared to those of senior scientists (e.g., postdoctoral researchers, department heads, professors and upper management).
- Type of employer: Scientists in academia versus scientists in non-academic institutions (NAI) (regardless of whether they were PhD candidates or Senior scientists)—respondents from academic institutions compared to those working in industry, hospitals, small and medium-sized enterprises (SMEs, as defined by H2020) governmental and nongovernmental organizations. As multiple answers were possible, whenever a respondent selected "academia", he/she was excluded from the "NAI" group, resulting in 113 respondents in the "academia" group and 38 in the "NAI" group.
- Main area of expertise: "experts with biology expertise" (66 respondents that selected only choices from the biology-based area), "experts with engineering expertise" (43 respondents that selected only choices from the engineering-based area) or "experts with interdisciplinary expertise" (38 respondents that selected at least one biology-based and one engineering-based area of expertise).

These categories were then analyzed with the same power query code written for the analysis of the overall data and compared to each other.

2.4. Graphical Representation of the Data

GraphPad Prism version 9.3.1 (471) for Windows (64-bit), GraphPad Software, San Diego, California USA (www.graphpad.com) was used solely to generate the graphical representation of the data. No statistical analysis was performed.

3. Results

3.1. Professional Profile of the Respondents

The answers to Q.1 of the survey revealed a diverse group of respondents with respect to their level of profession, their employer type and their main areas of expertise. Forty six percent of the respondents were *PhD candidates* and 51% comprised of *senior scientists* (Figure 1a).

With respect to the current employer, the most represented category was *Academia* (75%), which comprised universities and research institutes. Amongst *NAI*, *industry* was the most represented (19%) followed by *governmental organizations* (7%), *SMEs* (5%) and *hospitals* (5%) (Figure 1b). Additionally, most respondents worked in applied research, as expected in a multidisciplinary field. The main areas of expertise in biology and engineering were *cell and molecular biology* (58%) and *microfabrication/microfluidics* (46%), respectively. A quarter of the respondents selected at least one engineering and one biological option as main areas of expertise (Figure 1c).

To further analyze the expectations of the respondents towards training efforts, we sought to understand the respondents themselves, by analyzing their own career trajectory.

While most respondents held a bachelor's degree in basic sciences, such as *biochemistry/biology* (38%) or *engineering* (21%), we observed a shift towards interdisciplinary fields for postgraduate studies (Figure 2). A majority of the *PhD candidates* held a bachelor's, master's (33%, 46%) and were pursuing a PhD in *bioengineering*. *Senior scientists* on the other hand held most commonly a bachelor's and master's in *biochemistry/biology* (46% and 31%, respectively) and a doctorate degree in *bioengineering* (26%). The respondents in the *NAI category mostly held all three* degrees in *biochemistry/biology* (45% for bachelor's, 32% for master's and 23% for doctorate degrees). Researchers with *interdisciplinary expertise* gained it very early with a bachelor's in *bioengineering* (35%), followed by graduate or

postgraduate degrees in *bioengineering* as well (54% and 55%, respectively). While fewer respondents with *engineering expertise* (74%) pursued a doctorate degree than those with *biology* or *interdisciplinary expertise* (88%, 92%, respectively), they tended to switch towards bioengineering degrees at the master's and doctorate levels. Respondents with biology expertise spread across different disciplines such as *bioengineering, biochemistry/biology, pharmacology/toxicology* or *medicine* during doctorate studies. Moreover, 55% of them declared no familiarity with *microfabrication techniques* (Figure 3a) while the group with engineering expertise noted reasonable familiarity with *biological systems* (Figure 3b). Interestingly, there is no biological system-specific bias between biology, engineering and interdisciplinary experts.




Figure 1. Professional profile of the respondents: (**a**) Current professional level (**b**) Current type of employer (**c**) Areas of expertise, categorized by biology/engineering/interdisciplinary skills. Data in (**b**,**c**) is from questions in the questionnaire that allowed for multiple answers. The number of respondents is reflected in the figure legend and x axis while the number of responses is described near each bar. The data reflects the responses to Q1.b (**a**), Q1.a (**b**) and Q1.c (**b**), as well as Q1.g (**c**).




Figure 2. The academic background of all respondents (overall dataset) and the subgroups of *PhD* candidates, senior scientists, academia, Non-academic institutions and biology/engineering/interdisciplinary experts. The data reflects the responses to Q1.d, e and f.




Figure 3. Familiarity of interdisciplinary (N = 40), Biological (N = 66) and Engineering experts (N = 43) in (**a**) microfabrication techniques (**b**) with biological systems. The number of respondents for each specific microfabrication technique and biological system is presented cumulatively inside of the respective bars. The data reflects the responses to Q2 and Q3.

(149 Respondents)

3.2. Opinion of the Respondents on the State of Organ-on-Chip Development

Next, we explored which aspects of OoC technology the respondents deemed to be important for the development of the OoC field (Figure 4). These aspects were related to design or production (*e.g., usability* or *production scale-up*) and to the translation of OoC technology (*e.g., comparison with clinical data* or *qualification of models*). Undeniably, many of

а

b

the respondents considered *training* to be very important (67%) or somewhat important (28%), highlighting the importance of this study. The top three aspects considered very important, apart from *training* itself, were *definition of cell culture standards—function and origin of cells* (75%), *usability* (73%) and *qualification of the models* (64%).

		AIL (4/149)	Candidates	Acad	PHETON LE	1.36)	ay based th	eeing base	se ^{thrk31} (t ²³) se ^{chillen} (t ²³)	
	046	PHIL	Serri	PCO	12/21	BION	Eng.	Inter.		
Definition of specific cell culture standards (function and origin of cells)	3.7	3.7	3.8	3.7	3.8	3.9	3.5	3.8	4 - Very Important	
Usability –	3.7	3.8	3.7	3.7	3.7	3.8	3.6	3.7		
Training —	3.7	3.7	3.7	3.7	3.7	3.8	3.6	3.8		
Qualification of the models –	3.7	3.6	3.7	3.6	3.8	3.7	3.6	3.6		
Comparison with clinical data –	3.7	3.6	3.8	3.6	3.7	3.7	3.6	3.6		
Microfabrication techniques –	3.6	3.7	3.5	3.7	3.4	3.5	3.6	3.6		
Sensor integration and real-time monitoring	3.5	3.6	3.4	3.5	3.3	3.5	3.4	3.5		
High-throughput cultivation	3.4	3.6	3.3	3.4	3.3	3.5	3.5	3.2		
Production scale-up of Organ-on-Chip systems	3.4	3.5	3.4	3.5	3.3	3.4	3.4	3.4	3 - Somewhat Impo	rtant
Uptake by scientists from other fields –	3.3	3.5	3.2	3.4	3.0	3.3	3.3	3.4		
PKPD modeling —	3.2	3.3	3.2	3.2	3.4	3.3	3.2	3.1		
Comparison with animal data –	2.9	3.0	2.8	3.0	2.7	2.9	2.8	3.0	<2.5	
									2 - Less Important 1 - Not Important	

Figure 4. Assessment of the importance of aspects in OoC field development, from left to right for all respondents (overall dataset, N = 149), for the subgroups *PhD Candidates* vs. *Senior Scientists* (N = 69 + 79), for the subgroups *Academia* vs. *NAI* (N = 111 + 38) and categorized based on main expertise biology/engineering/interdisciplinary experts (N = 66 + 43 + 38). N = number of respondents, total and for each subgroup. The importance level was ranked by assigning values to the options to generate a ranking as follows: Very important = 4; Somewhat important = 3; Less important = 2; Not important = 1. We excluded respondents who skipped the question and those who answered "not sure". The heatmap contains the average ranking per response per group. The data reflects the responses to Q4.

PhD candidates considered usability (77%) as the most important aspect in contrast to senior scientists, who chose *definition of cell culture standards—function and origin of cells* (80%) and *comparison to clinical data* (44%). Scientists in *academia* considered *usability* very important (74%) while *NAI* respondents deemed the *definition of cell culture standards—function and origin of cells* (82%) as the most important aspects, followed by *qualification of the models* (76%). Biological experts, like *interdisciplinary experts*, considered *definition of cell culture standards—function and origin of cells* as the most important aspect, followed by *usability* (79% and 76%, respectively). Engineering experts concurrently identified *microfabrication techniques*, *usability* and *qualification* as the most important aspects (63%).

Stakeholder groups perform different roles and utilize OoC technology differently. Hence, they require different types of training, as reflected by the responses (Figure 5). As expected, the overall responses showed that the key aspects (rank > 3.5/5) for the training of *scientists-as-developers* were mostly engineering aspects (*biomaterials and microfluidic principles*) and *cell culture and stem cell technology*. For *scientists as end-users in academia*, the key aspects were *monitoring and analyzing (sensors, imaging, molecular biology/omics)*, while for *scientists as end-users in industry, pharmacology and toxicology principles* and *quality assurance* were at the forefront. Translational aspects such as *regulatory affairs, quality assurance* and *ethics* were the most important training aspects for *scientists as decision makers* (rank of >3.5/5), while the training for *technicians* could focus on *cell culture and stem cell technology*. The respondents also suggested that *clinicians* should be trained in *pharmacology and toxicity*.

principles and *ethics*, ranking most of the other aspects as less important (rank < 3.4/5). Interestingly, *PhD candidates* identified a need for training in *monitoring and analyzing* (sensors, imaging, molecular biology/omics), pharmacology and toxicology principles and quality assurance (rank of 3.7/5) as a priority for scientists as end-users in industry, conversely to senior scientists that identified pharmacology and toxicity principles (rank of 3.6/5). Overall, higher importance ranks were given by respondents with interdisciplinary expertise compared to biology or engineering experts, especially for topics such as monitoring and analyzing (sensors, imaging, molecular biology/omics), pharmacokinetic/pharmacodynamic (PKPD) modeling, pharmacology and toxicology principles and quality assurance. The opinion of respondents working in *NAI* is also differed from *Academia* by considering training in *microfabrication* for scientists-as-developers less important but attributing a higher rank to cell culture and stem cell technology.

						and the and th	6	aging) schology a navager putto putto a		2	omi	63)		
					anu	acturative analysing analy	in	aging) anasagin anasagin pkfr	nd pr	Jection D	blogy	al pinciple	5	
				, e ^c	andn	e	ensors in th	actinolitiner	nent ar ur	lolecin.	20	94 Print		
				echnique	ples	nalysing	stern cell	amanay	nalysing		nd toxicu	po reecommut Regul	incation .	.6
		alerials Nicro	mication	idic print	ing and	o ure and	ung. De	ing and	onodelling	cology?	assurant	o commu	alon atal	\$*
	Biom	ater Micro	hat where	Mur Mont	orn cell	culte Biob	ant Mori	on oker	Dr. phar	nac qual	N ^o Scier	ice Regu	all Ethic	\$
	3.6	3.5	3.6	3.5	3.6	2.9	3.3	3.1	3,1	3.5	3.2	2.9	2.9	 Scientists as developers
	3.0	2.7	3.1	3.6	3.7	3.2	3.6	3.3	3.4	3.1	3.3		3.2	 Scientists as end users (Academia)
Overall Response	2.8			3.5	3.5	3.4	3.5	3.5	3.6	3.6	3.1	3.5	3.3	 Scientists as end users (Industry)
(N=149)	2.8	2.7	2.7	2.9	3.1	3.1	3.0	3.1	3.3	3.6	3.5	3.7	3.7	 Scientist as decision-makers
	3.0 2.3	3.3 2.0	3.2 2.3	3.3 3.0	3.6 3.2	3.0 3.4	3.3 3.1	2.6 3.1	2.7 3.5	3.3 3.2	2.2 3.0	2.2 3.1	2.5 3.5	— Technicians — Clinicians
	3.6	3.8	3.7	3,5	3.6	2.9	3.3	3.2	3.1	3.5	3.3	2.9	3.0	 Scientists as developers
	3.1	2.9	3.2	3.7	3.7	3.4	3.7	3.5	3.5	3.2	3.3	2.9	3.3	 Scientists as end users (Academia)
PhD Candidates	2.9		3.0	3.7	3.5	3.6	3.7	3.6	3.7	3.7	3.2	3.5	3.5	 Scientists as end users (Industry)
(N=69)	3.0	3.1	2.9	3.1	3.2	3.1	3.1	3.3	3.4	3.7	3.7	3.7	3.7	 Scientist as decision-makers
	3.0	3.5	3.3	3.4	3.6	3.2	3.4	3.0	2.9	3.3	2.4	2.3	2.6	— Technicians — Clinicians
	2.4	2.2	2.4	3.0	3.3	3.2	3.1	3.2	3.6	3.2	3.0	3.0	3.3	Clinicians Scientists as developers
	3.5 3.0	3.4 2.5	3.5 3.1	3.4 3.4	3.7 3.7	2.8 3.0	3.2 3.5	3.0 3.2	3.2 3.3	3.4 3.1	3.1 3.3		2.9 3.1	 Scientists as developers Scientists as end users (Academia)
Senior Scientists	2.8		2.8	3.4	3.5	3.3	3.4	3.5	3.6	3.5	3.0	3.5	3.2	 Scientists as end users (Industry)
(N=79)	2.6		2.4	2.8	3.0	3.1	2.9	3.0	3.2	3.5	3.3	3.7	3.6	 Scientist as decision-makers
	3.0	3.1	3.1	3.2	3.6	2.7	3.2	2.4	2.5	3.3	2.1	2.0	2.4	— Technicians
	2.2	1.8	2.2	3.0	3.1	3.5	3.1	3.0	3.4	3.2	3.0	3.3	3.6	— Clinicians
	3.6	3.7	3.6	3.5	3.6	2.8	3.2	3.0	3.1	3.5	3.3	3.0	2.9	 Scientists as developers
	3.1 2.9		3.1 2.9	3.6 3.6	3.7 3.5	3.4 3.4	3.6 3.6	3.3 3.5	3.4 3.6	3.2 3.6	3.3 3.1	2.9	3.2 3.4	 Scientists as end users (Academia) Scientists as end users (Industry)
Academia	2.9			3.6 2.9	3.5	3.4 3.1	3.6 2.9	3.5	3.6	3.6 3.6	3.1	3.6 3.7	3.4 3.7	 Scientists as end users (industry) Scientist as decision-makers
(N=111)	3.0	3.3	3.1	3.3	3.6	3.0	3.2	2.7	2.7	3.3	2.2	2.2	2.5	- Technicians
	2.3	2.0	2.3	3.0	3.2	3.3	3.1	3.1	3.5	3.2	3.0	3.1	3.5	— Clinicians
	3.5	3.1	3.6	3.3	3.7	3.1	3.3	3.3	3.3	3.5	3.0	2.7	3.0	 Scientists as developers
	2.8	2.3	3.2	3.4	3.6	2.8	3.5	3.3	3.4	2.9	3.3	2.7	3.1	 Scientists as end users (Academia)
NAI	2.6			3.3	3.6	3.4	3.4	3.5	3.7	3.5	3.1	3.3	3.1	 Scientists as end users (Industry)
(N=38)	2.7 3.0	2.4	2.6	3.1 3.3	3.2 3.7	3.2 2.8	3.1 3.4	3.4 2.5	3.5 2.8	3.7 3.3	3.4 2.3	3.7 2.1	3.6 2.6	 Scientist as decision-makers Technicians
	2.2	1.9	2.3	3.0	3.3	3.4	3.4	3.1	2.0 3.6	3.2	3.1	3.3	3.6	- Clinicians
	3.6	3.5	3.6	3.5	3.7	3.0	3.3	3.1	3.1	3.6	3.2	2.9	3.0	 Scientists as developers
	3.0	2.6	3.2	3.6	3.7	3.3	3.6							
Biology-based	2.9							3.3	3.4	3.3	3.3		3.1	 Scientists as end users (Academia)
			3.1	3.6	3.6	3.4	3.5	3.5	3.4 3.6	3.3 3.6	3.3 3.2			 Scientists as end users (Academia) Scientists as end users (Industry)
expertise (N=66)	2.9			3.0	3.2	3.2	3.1	3.5 3.2	3.6 3.4	3.6 3.6	3.2 3.5	2.9	3.1 3.3 3.8	 Scientists as end users (Industry) Scientist as decision-makers
(N=66)	3.0	2.9 3.1	2.8 3.1	3.0 3.3	3.2 3.6	3.2 3.0	3.1 3.3	3.5 3.2 2.6	3.6 3.4 2.8	3.6 3.6 3.2	3.2 3.5 2.2	2.9 3.5 3.7 2.1	3.1 3.3 3.8 2.5	 Scientists as end users (Industry) Scientist as decision-makers Technicians
(N=66)	3.0 2.2	2.9 3.1 2.0	2.8 3.1 2.3	3.0 3.3 3.0	3.2 3.6 3.2	3.2 3.0 3.4	3.1 3.3 3.0	3.5 3.2 2.6 3.1	3.6 3.4 2.8 3.5	3.6 3.6 3.2 3.2	3.2 3.5 2.2 3.0	2.9 3.5 3.7 2.1 3.1	3.1 3.3 3.8 2.5 3.4	 Scientists as end users (Industry) Scientist as decision-makers Technicians Clinicians
(N=66)	3.0 2.2 3.5	2.9 3.1 2.0 3.5	2.8 3.1 2.3 3.6	3.0 3.3 3.0 3.4	3.2 3.6 3.2 3.6	3.2 3.0 3.4 2.6	3.1 3.3 3.0 3.1	3.5 3.2 2.6 3.1 3.2	3.6 3.4 2.8 3.5 3.2	3.6 3.6 3.2 3.2 3.2 3.3	3.2 3.5 2.2 3.0 3.3	2.9 3.5 3.7 2.1 3.1 2.9	3.1 3.3 3.8 2.5 3.4 2.9	Scientists as end users (Industry) Scientist as decision-makers Technicians Clinicians Scientists as developers
(N=66)	3.0 2.2	2.9 3.1 2.0 3.5 2.7	2.8 3.1 2.3 3.6 3.2	3.0 3.3 3.0 3.4 3.5	3.2 3.6 3.2	3.2 3.0 3.4 2.6 3.1	3.1 3.3 3.0	3.5 3.2 2.6 3.1 3.2 3.3	3.6 3.4 2.8 3.5 3.2 3.3	3.6 3.6 3.2 3.2 3.3 3.3 3.0	3.2 3.5 2.2 3.0 3.3 3.3 3.3	2.9 3.5 3.7 2.1 3.1 2.9 2.9	3.1 3.3 2.5 3.4 2.9 3.2	Scientists as end users (industry) Scientist as decision-makers Technicians Clinicians Scientists as developers Scientists as end users (Academia)
(N=66) Engineering-based expertise	3.0 2.2 3.5 3.2	2.9 3.1 2.0 3.5	2.8 3.1 2.3 3.6	3.0 3.3 3.0 3.4	3.2 3.6 3.2 3.6 3.7	3.2 3.0 3.4 2.6	3.1 3.3 3.0 3.1 3.5	3.5 3.2 2.6 3.1 3.2	3.6 3.4 2.8 3.5 3.2	3.6 3.6 3.2 3.2 3.2 3.3	3.2 3.5 2.2 3.0 3.3	2.9 3.5 3.7 2.1 3.1 2.9	3.1 3.3 3.8 2.5 3.4 2.9	Scientists as end users (Industry) Scientist as decision-makers Technicians Clinicians Scientists as developers
(N=66) Engineering-based	3.0 2.2 3.5 3.2 2.9	2.9 3.1 2.0 3.5 2.7 2.6 2.6 3.4	2.8 3.1 2.3 3.6 3.2 2.9 2.5 3.1	3.0 3.3 3.0 3.4 3.5 3.3 2.9 3.3	3.2 3.6 3.2 3.6 3.7 3.5	3.2 3.0 3.4 2.6 3.1 3.3	3.1 3.3 3.0 3.1 3.5 3.3	3.5 3.2 2.6 3.1 3.2 3.3 3.3	3.6 3.4 2.8 3.5 3.2 3.3 3.5	3.6 3.6 3.2 3.2 3.3 3.0 3.5	3.2 3.5 2.2 3.0 3.3 3.3 3.3 3.0	2.9 3.5 3.7 2.1 3.1 2.9 2.9 3.4	3.1 3.3 3.8 2.5 3.4 2.9 3.2 3.2	Scientists as end users (industry) Scientist as decision-makers Technicians Clinicians Scientists as developers Scientists as end users (Academia) Scientists as end users (industry)
(N=66) Engineering-based expertise	3.0 2.2 3.5 3.2 2.9 2.9	2.9 3.1 2.0 3.5 2.7 2.6 2.6	2.8 3.1 2.3 3.6 3.2 2.9 2.5	3.0 3.3 3.0 3.4 3.5 3.3 2.9	3.2 3.6 3.2 3.6 3.7 3.5 3.2	3.2 3.0 3.4 2.6 3.1 3.3 3.0	3.1 3.3 3.0 3.1 3.5 3.3 2.9	3.5 3.2 2.6 3.1 3.2 3.3 3.3 3.3 3.0	3.6 3.4 2.8 3.5 3.2 3.3 3.5 3.3	3.6 3.6 3.2 3.2 3.3 3.3 3.0 3.5 3.5	3.2 3.5 2.2 3.0 3.3 3.3 3.0 3.4	2.9 3.5 3.7 2.1 3.1 2.9 2.9 3.4 3.7	3.1 3.3 3.8 2.5 3.4 2.9 3.2 3.2 3.2 3.2	Scientists as end users (industry) Scientist as decision-makers Technicians Clinicians Scientists as developers Scientists as end users (Academia) Scientists as end users (industry) Scientist as decision-makers
(N=66) Engineering-based expertise	3.0 2.2 3.5 3.2 2.9 2.9 3.1 2.5 3.5	2.9 3.1 2.0 3.5 2.7 2.6 2.6 3.4 2.0 3.7	2.8 3.1 2.3 3.6 3.2 2.9 2.5 3.1 2.3 3.6	3.0 3.3 3.0 3.4 3.5 3.3 2.9 3.3 3.1 3.5	3.2 3.6 3.2 3.6 3.7 3.5 3.2 3.6 3.5 3.7	3.2 3.0 3.4 2.6 3.1 3.3 3.0 2.8 3.3 2.8	3.1 3.3 3.0 3.1 3.5 3.3 2.9 3.2 3.3 3.3	3.5 3.2 2.6 3.1 3.2 3.3 3.3 3.0 2.4 3.1 3.0	3.6 3.4 2.8 3.5 3.2 3.3 3.5 3.3 3.5 3.3 2.4 3.6 3.1	3.6 3.6 3.2 3.2 3.3 3.0 3.5 3.5 3.4 3.4 3.5	3.2 3.5 2.2 3.0 3.3 3.3 3.3 3.0 3.4 2.3 3.3 3.3	2.9 3.5 3.7 2.1 3.1 2.9 2.9 3.4 3.7 2.3 3.3 2.8	3.1 3.3 3.8 2.5 3.4 2.9 3.2 3.2 3.2 3.6 2.5 3.6 2.5 3.6 2.9	Scientists as end users (industry) Scientist as decision-makers Technicians Clinicians Scientists as developers Scientists as end users (Academia) Scientists as end users (Industry) Scientists as end users Technicians Clinicians Scientists as developers
(N=66) Engineering-based expertise	3.0 2.2 3.5 3.2 2.9 2.9 3.1 2.5 3.5 3.0	2.9 3.1 2.0 3.5 2.7 2.6 2.6 3.4 2.0 3.7 2.7	2.8 3.1 2.3 3.6 3.2 2.9 2.5 3.1 2.3 3.6 3.6 2.9	3.0 3.3 3.0 3.4 3.5 3.3 2.9 3.3 3.1 3.5 3.6	3.2 3.6 3.2 3.6 3.7 3.5 3.2 3.6 3.5 3.7 3.7 3.7	3.2 3.0 3.4 2.6 3.1 3.3 3.0 2.8 3.3 2.8 3.4	3.1 3.3 3.0 3.1 3.5 3.3 2.9 3.2 3.3 3.3 3.3 3.7	3.5 3.2 2.6 3.1 3.2 3.3 3.3 3.0 2.4 3.1 3.0 3.4	3.6 3.4 2.8 3.5 3.2 3.3 3.5 3.3 3.5 3.3 2.4 3.6 3.1 3.4	3.6 3.6 3.2 3.2 3.3 3.0 3.5 3.5 3.4 3.4 3.4 3.5 3.1	3.2 3.5 2.2 3.0 3.3 3.3 3.3 3.4 2.3 3.3 3.3 3.3 3.3	2.9 3.5 3.7 2.1 3.1 2.9 2.9 3.4 3.7 2.3 3.3 2.8 2.8 2.8	3.1 3.3 2.5 3.4 2.9 3.2 3.2 3.6 2.5 3.6 2.9 3.1	Scientists as end users (industry) Scientist as decision-makers Technicians Clinicians Scientists as developers Scientists as end users (Academia) Scientists as end users (industry) Scientist as decision-makers Technicians Clinicians Scientists as developers
(N=66) Engineering-based expertise (N=43) Interdisciplinary	3.0 2.2 3.5 3.2 2.9 2.9 3.1 2.5 3.5 3.0 2.7	2.9 3.1 2.0 3.5 2.7 2.6 2.6 3.4 2.0 3.7 2.7 2.7 2.6	2.8 3.1 2.3 3.6 3.2 2.9 2.5 3.1 2.3 3.6 2.9 2.6	3.0 3.3 3.0 3.4 3.5 3.3 2.9 3.3 3.1 3.5 3.6 3.7	3.2 3.6 3.2 3.6 3.7 3.5 3.2 3.6 3.5 3.7 3.7 3.7 3.4	3.2 3.0 3.4 2.6 3.1 3.3 3.0 2.8 3.3 2.8 3.3 2.8 3.4 3.5	3.1 3.3 3.0 3.1 3.5 3.3 2.9 3.2 3.3 3.3 3.3 3.7 3.7	3.5 3.2 2.6 3.1 3.2 3.3 3.3 3.0 2.4 3.1 3.0 3.4 3.7	3.6 3.4 2.8 3.5 3.2 3.3 3.5 3.3 3.5 3.3 2.4 3.6 3.1 3.4 3.7	3.6 3.6 3.2 3.2 3.3 3.0 3.5 3.5 3.4 3.4 3.4 3.4 3.5 3.1 3.7	3.2 3.5 2.2 3.0 3.3 3.3 3.3 3.3 3.4 2.3 3.3 3.3 3.3 3.3 3.3 3.3	2.9 3.5 3.7 2.1 3.1 2.9 2.9 3.4 3.7 2.3 3.3 2.8 2.8 2.8 3.7	3.1 3.3 2.5 3.4 2.9 3.2 3.2 3.6 2.5 3.6 2.5 3.6 2.9 3.1 3.5	Scientists as end users (industry) Scientist as decision-makers Technicians Clinicians Scientists as developers Scientists as end users (Academia) Scientists as end users (industry) Scientist as decision-makers Technicians Clinicians Scientists as end users (Academia) Scientists as developers Scientists as end users (Academia) Scientists as end users (Industry)
(N=66) Engineering-based expertise (N=43)	3.0 2.2 3.5 3.2 2.9 2.9 3.1 2.5 3.5 3.0	2.9 3.1 2.0 3.5 2.7 2.6 2.6 3.4 2.0 3.7 2.7	2.8 3.1 2.3 3.6 3.2 2.9 2.5 3.1 2.3 3.6 3.6 2.9	3.0 3.3 3.0 3.4 3.5 3.3 2.9 3.3 3.1 3.5 3.6	3.2 3.6 3.2 3.6 3.7 3.5 3.2 3.6 3.5 3.7 3.7 3.7	3.2 3.0 3.4 2.6 3.1 3.3 3.0 2.8 3.3 2.8 3.4	3.1 3.3 3.0 3.1 3.5 3.3 2.9 3.2 3.3 3.3 3.3 3.7	3.5 3.2 2.6 3.1 3.2 3.3 3.3 3.0 2.4 3.1 3.0 3.4	3.6 3.4 2.8 3.5 3.2 3.3 3.5 3.3 3.5 3.3 2.4 3.6 3.1 3.4	3.6 3.6 3.2 3.2 3.3 3.0 3.5 3.5 3.4 3.4 3.4 3.5 3.1	3.2 3.5 2.2 3.0 3.3 3.3 3.3 3.4 2.3 3.3 3.3 3.3 3.3	2.9 3.5 3.7 2.1 3.1 2.9 2.9 3.4 3.7 2.3 3.3 2.8 2.8 2.8	3.1 3.3 2.5 3.4 2.9 3.2 3.2 3.6 2.5 3.6 2.9 3.1	Scientists as end users (industry) Scientist as decision-makers Technicians Clinicians Scientists as developers Scientists as end users (Academia) Scientists as end users (industry) Scientist as decision-makers Technicians Clinicians Scientists as developers
(N=66) Engineering-based expertise (N=43)	3.0 2.2 3.5 3.2 2.9 2.9 3.1 2.5 3.5 3.0 2.7 2.5	2.9 3.1 2.0 3.5 2.7 2.6 2.6 3.4 2.0 3.7 2.7 2.6 2.5	2.8 3.1 2.3 3.6 3.2 2.9 2.5 3.1 2.3 3.6 2.9 2.6 2.5	3.0 3.3 3.0 3.4 3.5 3.3 2.9 3.3 3.1 3.5 3.6 3.7 2.9	3.2 3.6 3.2 3.6 3.7 3.5 3.2 3.6 3.5 3.7 3.7 3.7 3.4 2.7	3.2 3.0 3.4 2.6 3.1 3.3 3.0 2.8 3.3 2.8 3.4 3.5 3.1	3.1 3.3 3.0 3.1 3.5 3.3 2.9 3.2 3.3 3.3 3.7 3.7 3.7 2.8	3.5 3.2 2.6 3.1 3.2 3.3 3.3 3.0 2.4 3.1 3.0 3.4 3.7 3.1	3.6 3.4 2.8 3.5 3.2 3.3 3.5 3.3 2.4 3.6 3.1 3.4 3.7 3.2	3.6 3.6 3.2 3.2 3.3 3.0 3.5 3.5 3.4 3.4 3.4 3.5 3.1 3.7 3.7	3.2 3.5 2.2 3.0 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.3	2.9 3.5 3.7 2.1 3.1 2.9 3.4 3.7 2.3 3.3 2.8 2.8 2.8 3.7 2.8 3.7 3.7	3.1 3.3 2.5 3.4 2.9 3.2 3.2 3.6 2.5 3.6 2.9 3.1 3.5 3.5	Scientists as end users (industry) Scientist as decision-makers Technicians Clinicians Scientists as developers Scientists as end users (Academia) Scientists as end users (industry) Scientist as decision-makers Technicians Clinicians Scientists as end users (Academia) Scientists as developers Scientists as end users (Academia) Scientists as end users (Industry) Scientists as end users (Industry)

Figure 5. Aspects of training in OoC technology to be provided for the various stakeholders, opinions of all respondents (overall dataset, N = 149), *PhD candidates* vs. *senior scientists* (N = 69 + 79), biology/

engineering/interdisciplinary experts (N = 66 + 43 + 38) and *academia* vs. *non-academic institutions* (NAI) (N = 111 + 38). The importance level was ranked by assigning values to the options to generate a ranking as follows: Very important = 5; Somewhat important = 4; Less important = 3; Not important = 1. We excluded respondents who skipped the question and those who answered "not sure". The heatmap contains the average ranking per response and per group. The data reflects the responses to Q7–12. Engineering aspects include *Biomaterials*, microfabrication techniques *and manufacturability, microfluidic principles* and *monitoring and analysing (sensors, imaging)*. Biological aspects include *cell culture* and *stem cell technology, biobanking*, data management and protection, *monitoring and analysing* (molecular biology/omics), *PKPD modelling* and *pharmacology and toxicology principles*. Translational aspects include *quality assurance, science communication, regulatory affairs* and *ethics*.

3.3. Respondents Opinion on Specific Training Needs

The next question in the survey addressed the nature of the training to be provided to each stakeholder. Respondents were asked at which stage of their education the stakeholders should receive training, the duration of the training itself and in which fields of education OoC-specific training should be integrated.

Overall, training was deemed necessary in all stages of education (Figure 6a), particularly at a *master's* and *doctorate level* (70% and 81%, respectively). Only 1% of the respondents believed that training should begin only at a postdoctoral level, suggesting focus on OoC training at early stages of education. The respondents ranked as very important, the integration of OoC training in *bioengineering* degrees (122/144), followed by pharmacology/toxicology (86/120), while chemistry (13/119) was considered a low priority (Figure 6b). With respect to the intensity of the training, there was a strong agreement (79%) that scientists-as-developers should be trained in a specific postgraduate course (1 to 2 years) to develop deep knowledge and acquire practical skills (Figure 6c). One semester of training was recommended by respondents for scientists as end-users in academia (59%) and for scientists as end-users in industry (45%). However, 45% of the respondents considered 20 h of practical training adequate for scientists as end-users in industry. For scientists as decision *makers*, 48% of the respondents recommended gaining theoretical competence through 20 h of non-practical training. For technicians, 20 h of practical training were deemed enough to achieve competence in practical skills by most of the respondents (66%). With respect to *clinicians,* there was a consensus that they only require an *introductory awareness by receiving* up to 20 h of training, but the difference lies in the nature of training being practical (35%) or non-practical training (45%). The recommendation for the length of training programs progressively increased with the degree. Respondents suggested up to 20 h of practical or non-practical training at the bachelor's level while at least one semester at the PhD level.




Figure 6. The extent of training in OoC technology to be given to various stakeholders: (**a**) At what educational level the stakeholder should receive training, (**b**) STEM courses where OoC topic could be integrated. The importance level was ranked by assigning values to the options to generate a ranking as following: very important = 4; somewhat important = 3; less important = 2; not important = 1. We excluded respondents who skipped the question and those who answered "not sure". The heatmap contains the average ranking per response and per group. (**c**) Amount of theoretical and practical training each stakeholder should receive. The number of respondents for each specific amount of training is presented cumulatively inside of the respective bar. The data reflects the responses to Q6 (**a**), Q15 (**b**) and Q14 (**c**).

4. Discussion

The overall answers to the questionnaire clearly showed that there is a strong need to train the next generation of OoC researchers. The key needs are to increase end-user familiarity with chip development and production and to train *technicians* and *scientists as end-users* in quality assurance and qualification of OoC models. Early career researchers should be trained early on in OoC technology; courses should be included in applied science studies such as bioengineering, pharmacology/toxicology and biochemistry/biology.

The professional background of the respondents was essential to understand their answers and needs, and to draw conclusions about the direction that training in OoC technology should take for the next generation of researchers. Respondents currently enrolled in a doctoral program and actively involved in OoC research provided an important perspective that could guide training efforts given their current experiences. In our opinion, a young field such as OoC tends to have a larger presence in academia, and it could be useful to include more insight from researchers in industry for topics in this field in future surveys. Due to the different research approaches of academia and NAI, we placed particular focus on the comparison of these respondent groups, which revealed different levels of importance of the individual training aspects and in terms of who should receive training. The relevance of interdisciplinarity was also addressed and importantly, the new generations of researchers are already obtaining interdisciplinary training earlier in their careers. This is probably not specific to the OoC field but essential to identify training needs and justify our analysis according to the respondents biological, engineering, or interdisciplinary expertise. We also profiled the respondents based on the type of research they work on as *basic, translational and applied* research, but we did not include the definitions of each research type. In an interdisciplinary field, those definitions may substantially vary between the biology experts and engineering experts. Therefore, a comparison between those groups was not performed. It would have been also of interest to stratify the respondents according to the OoC technologies development stage (platform

was not available. Beyond training, the aspects usability, qualification and definition of cell culture standards in the OoC field were deemed to be of high importance. Interestingly, the data also suggests that the respondents do not see the comparison with animal and clinical data as important aspects by ranking them as the least important aspects. Many efforts have been made recently towards qualification and standardization of OoC technologies with initiatives from academia, regulatory agencies and industry. A recent technical report published by the European Centre for the Validation of Alternative Methods (ECVAM) highlights the interest of the research community in establishing the scientific validity of complex in vitro models, particularly OoCs [24]. This report also stated that OoCs further require standardization at both technical and biological levels and that investment in training in aspects of both regulatory and biomedical research is essential. More recently, initiatives on the standardization of OoC have been taking place [14,15] such as the European consortium Moore4medical.eu developing open technology platforms [25]. The WelcomeLeap foundation also launched the Hope program aiming at funding the development of organ platforms and connections. From the industry perspective, the Innovation and Quality Microphysiological Systems (IQ MPS) Affiliate, a consortium of pharmaceutical and biotechnology companies within the International Consortium for Innovation and Quality in Pharmaceutical Development (the IQ Consortium) identifies qualification as a key priority. Importantly, the IQ MPS states that qualification of OoCs, rather than validation in the OECD sense, is not trivial and cannot be dissociated from the context of use [12].

development, OoC design, biological applications, or regulatory use) but that information

In the 3Rs context, a 1:1 replacement of animal models is no longer a priority and it is generally accepted that the key lies in developing models with human relevance, thus enhancing their translational value and their acceptance in the larger scientific community [6,26]. Possibly, the low importance attributed to comparison with animal and clinical *data* reflects this vision that microphysiological systems mimicking the complexity of the human body are able to generate knowledge with a mechanistic understanding and that using relevant controls and a scientific agreement of standards is more important than direct comparisons of significantly different model systems. The importance of using in silico modelling was also identified as somewhat important for the development of the OoC field (rank of 4.2 for *PKPD modeling*) and as an important training need for end users in industry with a rank 4.4–4.7 from respondents of all groups. Interestingly, almost half of the respondents (45%), especially PhD Candidates and engineering experts responded "not sure" about the importance of *PKPD modeling* for training. *PKPD modeling* allows for correlation of in vitro data to in vivo responses [27,28] and possibly, this definition is not yet widely understood. A limitation of the employed questionnaire is the hiatus of questions with regard to the context of use of the OoC technologies, which could be a topic for future investigation. The context of use can shape the specific needs, which are possibly very different, for instance, for herbal products of food supplements industry, mainly interested in

PKPD and toxicological data, compared to pharmaceutical industry, with a higher interest in extracting safety and efficacy mechanistic information from OoC models.

Overall, the respondents mainly worked in *applied* (71%) and *basic research* (75%) as well as the *pharmaceutical industry* (15%) while other potential users in the *chemical and cosmetics industry* were underrepresented; potentially providing an explanation for the lower importance attributed to including training in OoC in chemistry study courses. This underrepresentation of industrial end users other than those from the pharmaceutical industry is mirrored in the overall OoC community, with the hesitancy and challenges of using novel complex model systems for regulatory toxicology being a possible reason.

Most of the respondents were expected to have experienced the challenges of working in multidisciplinary teams throughout their careers. Hence, interdisciplinary training was considered important for *scientists-as-developers* that connects the engineering aspects of the devices to their biological application. Moreover, training should start at early stages and should be integrated into interdisciplinary courses (e.g., bioengineering), to allow for sustainable development of this field. To the best of our knowledge, training activities in the bachelor's and master's levels of study were mostly unstructured and often limited to an introductory lecture integrated within broader semester topics for different programs. Hands-on training for OoCs has also been provided directly by companies that sell microfluidic cell culture systems. Although hands-on training promoted by companies is a valuable contribution, it does not provide broad training and is often coupled with marketing interests. Such training actions are also commonly limited to a maximum of two-day sessions. PhD Candidates and postdoctoral researchers are the stakeholders with more diverse training opportunities. At a European level, training provided by the Netherlands Organ-on-Chip Initiative (NOCI) and the Marie Skłodowska-Curie Innovative Training Network (MSCA-ITN) EUROoC are good examples of strategies to gather diverse knowledge for training PhD candidates. Both initiatives bring together experts from stem cell biology, microfabrication, medical ethics, genetics, electronics, microfluidics and other fields to provide training for PhD candidates. These networks include partners from the academic sector, industrial sector, SMEs and regulatory authorities highlighting the importance of integrative training for the next generation of scientists.

Multidisciplinary, interdisciplinary, and transdisciplinary curriculum development and implementation is a recognized challenge [18,29]. Miranda et al. proposed to integrate four core components for a multidisciplinary training [30]: (i) competencies (hard and soft skills), (ii) learning methods (challenge- and problem-based learning), (iii) information and communication technologies (digital tools and platforms), and (iv) infrastructure (hands-on and classroom training). To approach interdisciplinary training at the institutional/university level, several concepts have been introduced, e.g., the creation of academic units within universities, so called *interdisciplinary organizations*, in parallel with the subject-specific structure of departments [31]. Interdisciplinary organizations allow us to unify different STEM research areas (e.g., engineers, biochemists, toxicologists) to target a specific problem. Conversely, Takeuchi et al. suggest that STEM education should be transdisciplinary, defining it as more than the sum of the independent STEM disciplines and as an iterative and synergistic use of competencies from those disciplines [18]. This term was, however, not used or defined in our survey. It would have been interesting to further explore the understanding and opinion of the respondents to the importance of integrative transdisciplinary training. Indeed, transdisciplinary training requires innovative approaches, namely, creativity and problem-based learning, for which there is no reference in the literature on OoC specifically and is still a growing approach facing implementation challenges in STEM fields in general [32].

Respondents at the level of *PhD candidates* started an interdisciplinary career pathway earlier than *senior scientists*. Younger generations of scientists have likely recognized the importance of multidisciplinary training to achieve success in bridging biology and engineering concepts to develop or apply OoC technologies. However, the academic career choices of *senior scientists* working in the OoC field differed, suggesting that most

of the *senior scientists* started engaging in multidisciplinary training later in their career and probably not through a formal academic degree. *PhD candidates* also considered interdisciplinary training to be important to promote *awareness and uptake of OoCs* by scientists from other fields.

The higher interdisciplinary background of *Academia* compared to *NAI* may be the reason why the responses of *academia* leaned towards engineering topics and promoting the uptake by other scientists while *NAI* considered that training in cell culture and translational topics were needed over engineering. This suggests that *scientists-as-developers* likely worked in academia while *NAIs* mainly comprise *end-users* of OoC products. Respondents in *NAIs* had a deeper *pharmacology/toxicology* background, while *academia* has a *bioengineering* background—two important aspects for OoC application. This points towards an opportunity where training efforts could bridge these currently separate sets of expertise through the sharing of knowledge [33,34].

Respondents with *interdisciplinary expertise* attributed higher importance to training in both biological and engineering aspects. Another striking difference is that *engineering* experts showed a certain degree of familiarity with biological systems that is essential for proper OoC design and fabrication but are not sure or did not respond concerning the importance of *PKPD modeling* (69%). Contrarily, the understanding of the microfabrication techniques and bioengineering principles seemed not to be essential for *biological experts*, who likely considered themselves as end users. However, a better understanding of the material, design and fabrication concepts and limitations from the end users could bring a faster and more productive development of innovative OoC. Additionally, monitoring and analyzing was particularly highlighted by respondents with interdisciplinary expertise and *PhD candidates*, possibly reflecting the importance of considering the biological endpoints at the stage of *OoC design and development* as well as the diversity of skills required to analyze the data covering physics, chemistry, and molecular biology expertise, among others [35–37]. These observations could point towards a potential training avenue targeting the biology experts. Importantly, the OoC field is an example of the emerging need for transdisciplinary education [38,39]. To be an OoC expert, one needs biological and engineering expertise and needs to be able to see though both lenses in an integrated way and using a common language [14].

Based on a thorough analysis of responses from more than 100 experts with different scientific backgrounds and from different sectors, we drew several key conclusions and provide an answer to the three overarching questions formulated initially:

- 1. Which **aspects of training** are the most important for the overall development of the OoC field?
 - Definition of cell culture standards
 - OoC usability
- 2. Which **specific type of training** in the OoC field should each stakeholder receive?
 - Scientists-as-end-users with a biology background should be trained in microfabrication and microfluidics principles.
 - *Scientists-as-developers* should be trained in *pharmacology/toxicology*.
- 3. What is the **amount of training** that each stakeholder should receive to achieve a certain level of experience in the OoC field?
 - Scientists-as-developers should undergo specific post graduate training (1–2 years).
 - *Scientists-as-end-users* should undergo specific *practical training* (*up to 20 h*) and *seminars/courses integrated in a broader training*.

This work allowed us to identify the training priorities, key skill sets and adequate types of training from the perspective of each stakeholder. However, its limitations included the low participant number, primarily caused by the still-small number of researchers in this emerging field, and the discrepancy between the number of respondents between some groups, e.g., *academia* and *NAIs*. Recruiting consisted in social media publications, direct contacting of experts based on their scientific publication record and in the EUROOCs

annual meetings in 2019 and 2020 (online). The field is still relatively small and the number of stakeholders in academia outnumbers the other groups. For this reason, the analysis of the importance of OoC aspects and respective aspects of training in OoC technology to be provided for the various stakeholders is presented based on group specific responses (Figures 3–5). The overall stakeholder opinion on the educational level and the amount and the type of courses in which OoC topics should be integrated was selected to better guide the design of future training programs. In this analysis, there is a possible bias towards the opinions of the academic group due to its high representation. Future studies should target more specific training strategies towards the application of OoC technologies in a more mature, diverse and numerous community. In conclusion, the information collected and analyzed in this study could foster STEM undergraduate and graduate education in this technology and result in well-qualified and competent transdisciplinary professionals, who will continue exploring and successfully applying OoC technology.

Supplementary Materials: The following supporting information can be downloaded at: https://www.biorxiv.org/content/10.1101/2022.08.03.502617v1.supplementary-material, Supplementary File S1: Questionnaire; Supplementary File S2: AnalyzedData_NumberAnswers; Supplementary File S3_Rawdata_PQscript.

Author Contributions: Conceptualization, M.C. and P.L.; methodology, M.C., A.M., T.S. and S.K.; software, A.M.; validation, T.S., S.K. and P.L.; formal analysis, M.C. and A.M.; investigation, M.C., T.S. and A.M.; resources, P.L.; data curation, A.M. and M.C.; writing—original draft preparation, M.C., T.S. and A.M.; writing—review and editing, S.K., P.L. and T.S.; visualization, M.C. and S.K.; supervision, M.C. and P.L.; project administration M.C., P.L. and S.K.; funding acquisition, P.L. All authors have read and agreed to the published version of the manuscript.

Funding: This research has been supported by the H2020, European Commission. In particular, the CSA—Coordination and support action (GA-766884-ORCHID), the MSCA-ITN-ETN—European Training Networks (GA-812954-EUROoC) and the MSCA-IF-EF-ST—Standard EF to MC (GA-845147-LIV-AD-ON-A-CHIP). Further financial support was given by the Ministry of Science, Research and the Arts of Baden-Württemberg.

Informed Consent Statement: All respondents gave their informed consent for the publication of the results of this study, as described in the survey introductory text (Supplementary material 1). The survey was performed anonymously and in accordance with the European GDPR law.

Data Availability Statement: All data and analysis code are available in the supplementary files.

Acknowledgments: The authors kindly thank all the respondents for their time and for their help in distributing the questionnaire with a special thanks to Janny van den Eijnden-van Raaij for her advice and support *during the drafting of the questionnaire, its dissemination and on early discussions on the results.* We also thank the support of the Open Access Publishing Fund of University of Tübingen.

Conflicts of Interest: The authors declare no conflict of interest.

References

- Mastrangeli, M.; Partners, T.O.; Millet, S.; Raaij, J.V.D.E.-V. Organ-on-chip in development: Towards a roadmap for organs-on-chip. *ALTEX* 2019, *36*, 650–668. [CrossRef] [PubMed]
- Rudmann, D.G. The Emergence of Microphysiological Systems (Organs-on-chips) as Paradigm-changing Tools for Toxicologic Pathology. *Toxicol. Pathol.* 2019, 47, 4–10. [CrossRef] [PubMed]
- van den Berg, A.; Mummery, C.L.; Passier, R.; Van Der Meer, A.D. Personalised organs-on-chips: Functional testing for precision medicine. *Lab Chip* 2019, 19, 198–205. [CrossRef] [PubMed]
- Franzen, N.; van Harten, W.H.; Retèl, V.P.; Loskill, P.; van den Eijnden-van Raaij, J.; Ijzerman, M. Impact of organ-on-a-chip technology on pharmaceutical R&D costs. *Drug Discov. Today* 2019, 24, 1720–1724. [CrossRef] [PubMed]
- Peck, R.W.; Hinojosa, C.D.; Hamilton, G.A. Organs-on-Chips in Clinical Pharmacology: Putting the Patient Into the Center of Treatment Selection and Drug Development. *Clin. Pharmacol. Ther.* 2020, 107, 181–185. [CrossRef] [PubMed]
- 6. Herrmann, K. Beyond the 3Rs: Expanding the use of human-relevant replacement methods in biomedical research. *ALTEX Altern. Anim. Exp.* **2019**, *36*, 343–352. [CrossRef]
- Hippenstiel, S.; Thöne-Reineke, C.; Kurreck, J. Animal experiments: EU is pushing to find substitutes fast. *Nature* 2021, 600, 37. [CrossRef]

- 8. Sohn, L.L.; Schwille, P.; Hierlemann, A.; Tay, S.; Samitier, J.; Fu, J.; Loskill, P. How Can Microfluidic and Microfabrication Approaches Make Experiments More Physiologically Relevant? *Cell Syst.* **2020**, *11*, 209–211. [CrossRef]
- 9. OECD. Guidance Document on Good. In *Vitro Method Practices (GIVIMP);* OECD Series on Testing and Assessment; OECD: No. 286; OECD Publishing: Paris, France, 2018. [CrossRef]
- Mastrangeli, M.; Millet, S.; Mummery, C.; Loskill, P.; Braeken, D.; Eberle, W.; Cipriano, M.; Fernandez, L.; Graef, M.; Gidrol, X.; et al. Building Blocks for a European Organ-on-Chip Roadmap. *ALTEX Altern. Anim. Exp.* 2019, *36*, 481–492. [CrossRef]
- Marx, U.; Akabane, T.; Andersson, T.B.; Baker, E.; Beilmann, M.; Beken, S.; Brendler-Schwaab, S.; Cirit, M.; David, R.; Dehne, E.-M.; et al. Biology-inspired microphysiological systems to advance medicines for patient benefit and animal welfare. *ALTEX* 2020, *37*, 365–394. [CrossRef]
- 12. Baran, S.W.; Brown, P.C.; Baudy, A.R.; Fitzpatrick, S.C.; Frantz, C.; Fullerton, A.; Gan, J.; Hardwick, R.N.; Hillgren, K.M.; Kopec, A.K.; et al. Perspectives on the evaluation and adoption of complex in vitro models in drug development: Workshop with the FDA and the pharmaceutical industry (IQ MPS Affiliate). *ALTEX Altern. Anim. Exp.* **2022**, *39*, 297–314. [CrossRef]
- 13. Allwardt, V.; Ainscough, A.J.; Viswanathan, P.; Sherrod, S.D.; McLean, J.A.; Haddrick, M.; Pensabene, V. Translational Roadmap for the Organs-on-a-Chip Industry toward Broad Adoption. *Bioengineering* **2020**, *7*, 112. [CrossRef] [PubMed]
- 14. Mastrangeli, M.; Raaij, J.V.D.E.-V. Organs-on-chip: The way forward. Stem Cell Rep. 2021, 16, 2037–2043. [CrossRef] [PubMed]
- Piergiovanni, M.; Leite, S.B.; Corvi, R.; Whelan, M. Standardisation needs for organ on chip devices. *Lab Chip* 2021, 21, 2857–2868. [CrossRef] [PubMed]
- 16. Singer, A.; Montgomery, G.; Schmoll, S. How to foster the formation of STEM identity: Studying diversity in an authentic learning environment. *Int. J. STEM Educ.* 2020, *7*, 57. [CrossRef]
- 17. Stella, M.; de Nigris, S.; Aloric, A.; Siew, C.S.Q. Forma mentis networks quantify crucial differences in STEM perception between students and experts. *PLoS ONE* **2019**, *14*, e0222870. [CrossRef]
- Takeuchi, M.A.; Sengupta, P.; Shanahan, M.-C.; Adams, J.D.; Hachem, M. Transdisciplinarity in STEM education: A critical review. *Stud. Sci. Educ.* 2020, *56*, 213–253. [CrossRef]
- Choi, B.C.K.; Pak, A.W.P. Multidisciplinarity, interdisciplinarity and transdisciplinarity in health research, services, education and policy: 1. Definitions, objectives, and evidence of effectiveness. *Clin. Investig. Med.* 2007, 29, 351–364.
- 20. Federer, L.M.; Lu, Y.-L.; Joubert, D.J. Data literacy training needs of biomedical researchers. J. Med. Libr. Assoc. 2016, 104, 52–57. [CrossRef]
- 21. Weber, R.J.M.; Winder, C.L.; Larcombe, L.D.; Dunn, W.B.; Viant, M.R. Training needs in metabolomics. *Metabolomics* 2015, 11, 784–786. [CrossRef]
- 22. Barratt, H.; Fulop, N.J. Building capacity to use and undertake research in health organisations: A survey of training needs and priorities among staff. *BMJ Open* **2016**, *6*, e012557. [CrossRef] [PubMed]
- Carracedo, F.S.; Soler, A.; Martín, C.; López, D.; Ageno, A.; Cabré, J.; Garcia, J.; Aranda, J.; Gibert, K. Competency Maps: An Effective Model to Integrate Professional Competencies Across a STEM Curriculum. J. Sci. Educ. Technol. 2018, 27, 448–468. [CrossRef]
- Batista Leite, S.; Cipriano, M.; Capri, D.; Coecke, S.; Holloway, M.; Corvi, R.; Worth, A.; Barroso, J.; Whelan, M. Establishing the Scientific Validity of Complex In Vitro Models: Results of a EURL ECVAM Survey; EUR 30556 EN; Publications Office of the European Union: Luxembourg, 2021; ISBN 978-92-76-28410-9.
- Mastrangeli, M.; Aydogmus, H.; Dostanic, M.; Motreuil-Ragot, P.; Revyn, N.; De Wagenaar, B.; Dekker, R.; Sarro, P.M. Microelectromechanical Organs-on-Chip. In Proceedings of the 2021 21st International Conference on Solid-State Sensors, Actuators and Microsystems (Transducers), Orlando, FL, USA, 20–24 June 2021; pp. 102–107.
- 26. Loskill, P.; Hardwick, R.N.; Roth, A. Challenging the pipeline. *Stem Cell Rep.* 2021, *16*, 2033–2037. [CrossRef] [PubMed]
- Maass, C.; Stokes, C.L.; Griffith, L.G.; Cirit, M. Multi-functional scaling methodology for translational pharmacokinetic and pharmacodynamic applications using integrated microphysiological systems (MPS). *Integr. Biol.* 2017, *9*, 290–302. [CrossRef]
- Cirit, M.; Stokes, C.L. Maximizing the Impact of Microphysiological Systems with: In Vitro—In Vivo Translation. Lab Chip 2018, 18, 1831–1837. [CrossRef]
- 29. Budwig, N.; Alexander, A.J. A Transdisciplinary Approach to Student Learning and Development in University Settings. *Front. Psychol.* **2020**, *11*, 576250. [CrossRef]
- Miranda, J.; Navarrete, C.; Noguez, J.; Molina-Espinosa, J.-M.; Ramírez-Montoya, M.-S.; Navarro-Tuch, S.A.; Bustamante-Bello, M.-R.; Rosas-Fernández, J.-B.; Molina, A. The core components of education 4.0 in higher education: Three case studies in engineering education. *Comput. Electr. Eng.* 2021, 93, 107278. [CrossRef]
- 31. Yang, L.; Albats, E.; Etzkowitz, H. Interdisciplinary organization as a basic academic unit? Ind. High. Educ. 2021, 35, 173–187. [CrossRef]
- 32. Velez, A.-L.; Hall, R.P.; Lewis, S.N. Designing transdisciplinarity: Exploring institutional drivers and barriers to collaborative transdisciplinary teaching. *J. Public Aff. Educ.* **2022**, *28*, 138–155. [CrossRef]
- 33. Esch, E.W.; Bahinski, A.; Huh, D. Organs-on-chips at the frontiers of drug discovery. *Nat. Rev. Drug Discov.* 2015, 14, 248–260. [CrossRef]
- Holley, T.; Bowe, G.; Campia, I.; Belz, S.; Berggren, E.; Janusch Roi, A.; Wittwehr, C.; Whelan, M. Accelerating Progress in the Replacement, Reduction and Refinement of Animal Testing through Better Knowledge Sharing; UR 28234 EN; Publications Office of the European Union: Luxembourg, 2016.

- 35. Rogal, J.; Schlünder, K.; Loskill, P. Developer's Guide to an Organ-on-Chip Model. *ACS Biomater. Sci. Eng.* **2022**, *8*, 4643–4647. [CrossRef] [PubMed]
- 36. Fuchs, S.; Johansson, S.; Tjell, A.; Werr, G.; Mayr, T.; Tenje, M. In-Line Analysis of Organ-on-Chip Systems with Sensors: Integration, Fabrication, Challenges, and Potential. *ACS Biomater. Sci. Eng.* **2021**, *7*, 2926–2948. [CrossRef]
- Zhou, L.; Liu, L.; Chang, M.A.; Ma, C.; Chen, W.; Chen, P. Spatiotemporal dissection of tumor microenvironment via in-situ sensing and monitoring in tumor-on-a-chip. *Biosens. Bioelectron.* 2023, 225, 115064. [CrossRef]
- 38. Beebe, D.J.; Ingber, D.E.; Toonder, J.D. Organs on Chips 2013. Lab Chip 2013, 13, 3447–3448. [CrossRef] [PubMed]
- 39. Ramadan, Q.; Zourob, M. Organ-on-a-chip engineering: Toward bridging the gap between lab and industry. *Biomicrofluidics* **2020**, 14, 041501. [CrossRef] [PubMed]

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.